BR112012029067A2 - grupos-alvo de receptor do complemento 2 (cr2) melhorados. - Google Patents

grupos-alvo de receptor do complemento 2 (cr2) melhorados.

Info

Publication number
BR112012029067A2
BR112012029067A2 BR112012029067A BR112012029067A BR112012029067A2 BR 112012029067 A2 BR112012029067 A2 BR 112012029067A2 BR 112012029067 A BR112012029067 A BR 112012029067A BR 112012029067 A BR112012029067 A BR 112012029067A BR 112012029067 A2 BR112012029067 A2 BR 112012029067A2
Authority
BR
Brazil
Prior art keywords
complement
receptor
target groups
target
modulators
Prior art date
Application number
BR112012029067A
Other languages
English (en)
Inventor
Kovacs James
P Hannan Jonathan
Michael Holera V
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of BR112012029067A2 publication Critical patent/BR112012029067A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Abstract

grupos-alvos de receptor do ocmplemento 2 (cr2) melhorados - são providos aqui métodos e composições direcionados a proteínas solúveis que podem distribuir seletivamente moduladores de atividade do complemento. a entrega direcionada destes moduladores é alcançada através da mutação seletiva de aminoácidos particulares em uma porção de proteína alvo da composição correspondendo a pelo menos os dois primeiros domínios scr n-terminal de cr2. dependendo da combinação particular das mutações introduzidas na porção alvo, um modulador de atividade do complemento pode ser seletivamente entregue a ligantes particulares de cr2 em sítios onde a supressão ou a ativação de sistema do complemento é desejada.
BR112012029067A 2010-05-14 2011-05-13 grupos-alvo de receptor do complemento 2 (cr2) melhorados. BR112012029067A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34503510P 2010-05-14 2010-05-14
PCT/US2011/036552 WO2011143637A1 (en) 2010-05-14 2011-05-13 Improved complement receptor 2 (cr2) targeting groups

Publications (1)

Publication Number Publication Date
BR112012029067A2 true BR112012029067A2 (pt) 2019-09-24

Family

ID=44914740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029067A BR112012029067A2 (pt) 2010-05-14 2011-05-13 grupos-alvo de receptor do complemento 2 (cr2) melhorados.

Country Status (18)

Country Link
US (1) US9650447B2 (pt)
EP (1) EP2569332B1 (pt)
JP (1) JP5986990B2 (pt)
KR (1) KR20130080443A (pt)
CN (1) CN103038252A (pt)
AU (1) AU2011252864B2 (pt)
BR (1) BR112012029067A2 (pt)
CA (1) CA2799192A1 (pt)
CO (1) CO6650414A2 (pt)
EA (1) EA201291241A1 (pt)
ES (1) ES2717912T3 (pt)
IL (1) IL222881A0 (pt)
MX (1) MX2012013233A (pt)
NZ (1) NZ603560A (pt)
SG (1) SG185483A1 (pt)
TR (1) TR201904224T4 (pt)
WO (1) WO2011143637A1 (pt)
ZA (1) ZA201208579B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
AU2006249835B2 (en) 2005-05-26 2011-09-08 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
ES2507542T3 (es) 2007-03-14 2014-10-15 Alexion Cambridge Corporation Anticuerpo anti-factor B humanizado
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
EP2569332B1 (en) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
CN103476429B (zh) 2010-09-03 2016-08-24 施特姆森特克斯股份有限公司 新型调节剂及使用方法
WO2012095519A1 (en) * 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
WO2015184050A1 (en) * 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
US20180021376A1 (en) * 2011-03-04 2018-01-25 Rare Antibody Antigen Supply, Inc. Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CN105683759B (zh) 2013-08-07 2019-03-29 瑞颂医药公司 非典型溶血性尿毒综合征(aHUS)生物标志物蛋白
US20190016766A1 (en) * 2015-10-07 2019-01-17 Daniel E. Benjamin Use of improved modulators of complement function as cancer therapeutics
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
KR20210013091A (ko) * 2018-05-16 2021-02-03 시에스엘 리미티드 가용성 보체 수용체 1형 변이체 및 이의 용도
CN109929026B (zh) * 2019-03-15 2020-10-13 北京康普美特创新医药科技有限责任公司 人源靶向补体抑制物蛋白mCR2-DAF及应用
MX2021012997A (es) * 2019-04-24 2022-03-04 Univ Pennsylvania Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos.
CN110128547B (zh) * 2019-05-07 2022-07-22 北京康普美特创新医药科技有限责任公司 人源靶向补体抑制物蛋白mCR2-fH及应用
GB201912437D0 (en) * 2019-08-30 2019-10-16 Glaxosmithkline Ip Dev Ltd CR2 Binding Proteins and their use in Medical Therapy
CN111763243B (zh) * 2020-05-22 2021-01-29 浙江海洋大学 小公鱼免疫活性肽及其制备方法和用途
WO2022251446A1 (en) 2021-05-28 2022-12-01 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981481A (en) 1974-12-06 1999-11-09 The Johns Hopkins University Human C3b/C4b receptor (CR1)
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
DE3830271A1 (de) 1988-09-06 1990-03-15 Goetze Otto Mittel mit immunsuppressiver wirkung
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2648133B1 (fr) 1989-06-08 1992-02-21 Sanofi Sa Lauramides n-substitues, leur preparation et compositions les contenant
US5331090A (en) 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5310729A (en) 1990-04-20 1994-05-10 California Institute Of Biological Research Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
CA2203364A1 (en) 1994-10-25 1996-05-02 Jean-Yves Marcel Paul Bonnefoy Binding agents for treatment of inflammatory, autoimmune or allergic diseases
AU3487697A (en) 1996-06-14 1998-01-07 Johns Hopkins University School Of Medicine, The Use of chimeric vaccinia virus complement control proteins to inhibit complement
US5922320A (en) 1996-06-14 1999-07-13 Georgetown University Recombinant proCVF
WO1998007835A2 (en) 1996-08-21 1998-02-26 Sugen, Inc. Crystal structures of a protein tyrosine kinase
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
GB9624731D0 (en) 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
AU8296098A (en) 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US6503947B1 (en) 1998-01-27 2003-01-07 Brigham And Women's Hospital Method of treating cytotoxic damage
CN101298481A (zh) 1998-02-20 2008-11-05 吉宁特有限公司 补体活化的抑制剂
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
CA2331258C (en) 1998-06-12 2011-09-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
EP1001021B1 (en) 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
CN1202128C (zh) 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0008582D0 (en) 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
WO2001084149A2 (en) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7439330B2 (en) 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
EP1379266B1 (en) 2001-02-21 2007-04-18 SurroMed, Inc. Modified annexin proteins and prevention and treatment of thrombosis
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
WO2002092011A2 (en) 2001-05-17 2002-11-21 La Jolla Pharmaceutical Company Methods of treating antibody-mediated pathologies using agents which inhibit cd21
WO2003018774A2 (en) 2001-08-29 2003-03-06 University Of Virginia Patent Foundation Therapeutic uses of complement receptor 2
EP1336618A1 (en) 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Porcine complement regulator factor H and its use
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
EP1569685B8 (en) 2002-11-15 2012-12-05 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20070134260A1 (en) 2003-03-28 2007-06-14 Georg Feger Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
WO2004103288A2 (en) 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
JP4029772B2 (ja) 2003-05-16 2008-01-09 株式会社日立製作所 磁気ヘッドおよびそれを用いた磁気記録再生装置
EP1488798A1 (en) 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1682179A4 (en) 2003-11-05 2008-09-03 Palingen Inc INCREASED CYTOTOXICITY OF CDIM BINDING ANTIBODY AGAINST B LYMPHOCYTES
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
CN1925871A (zh) 2004-01-27 2007-03-07 南加州大学 聚合物结合的抗体癌症治疗剂
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
WO2005077417A1 (en) 2004-02-10 2005-08-25 The Regents Of The University Of Colorado Inhibition of factor b, the alternative complement pathway and methods related thereto
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1797118A2 (en) 2004-09-03 2007-06-20 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2588270A1 (en) 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
JP2008527005A (ja) 2005-01-14 2008-07-24 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア ドルーゼン形成を阻害するため、およびドルーゼン関連障害を診断または治療するための組成物および方法
CA2597411C (en) 2005-02-14 2014-08-12 University Of Iowa Research Foundation Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
AU2006249835B2 (en) 2005-05-26 2011-09-08 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US20090087907A1 (en) 2005-07-29 2009-04-02 Alice Pebay Compositions and Methods for Growth of Pluripotent Cells
KR20080052657A (ko) 2005-09-08 2008-06-11 디에스엠 아이피 어셋츠 비.브이. 노인성 황반 변성의 치료 또는 예방 방법
WO2007035857A2 (en) 2005-09-19 2007-03-29 Palingen, Inc. Treatment of b cell diseases using anti-germline antibody binding agents
HUE026423T2 (en) 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
US20110014270A1 (en) 2006-03-27 2011-01-20 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury and related conditions
BRPI0710826A2 (pt) 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
US7705475B2 (en) 2006-08-03 2010-04-27 Stats Chippac Ltd. Integrated circuit package system
TWI472535B (zh) 2006-11-02 2015-02-11 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
ES2507542T3 (es) 2007-03-14 2014-10-15 Alexion Cambridge Corporation Anticuerpo anti-factor B humanizado
WO2009029669A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
MX2009013082A (es) 2007-06-07 2010-01-15 Genentech Inc Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
US8435512B2 (en) 2008-03-03 2013-05-07 Novelmed Therapeutics, Inc. Anti-properdin antibodies
RS54113B1 (en) 2008-08-05 2015-12-31 Novartis Ag COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
WO2010033868A2 (en) * 2008-09-19 2010-03-25 Taligen Therapeutics, Inc. Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
WO2010091183A2 (en) * 2009-02-04 2010-08-12 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
EP2569332B1 (en) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
CN103248395A (zh) 2012-02-09 2013-08-14 中兴通讯股份有限公司 一种窄带干扰抑制方法及装置
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody

Also Published As

Publication number Publication date
MX2012013233A (es) 2013-05-20
US9650447B2 (en) 2017-05-16
AU2011252864A1 (en) 2012-11-29
SG185483A1 (en) 2012-12-28
CN103038252A (zh) 2013-04-10
AU2011252864B2 (en) 2015-11-05
US20130190477A1 (en) 2013-07-25
CO6650414A2 (es) 2013-04-15
EP2569332A1 (en) 2013-03-20
ES2717912T3 (es) 2019-06-26
EP2569332B1 (en) 2019-01-09
JP5986990B2 (ja) 2016-09-06
EA201291241A1 (ru) 2013-05-30
IL222881A0 (en) 2012-12-31
WO2011143637A1 (en) 2011-11-17
CA2799192A1 (en) 2011-11-17
KR20130080443A (ko) 2013-07-12
EP2569332A4 (en) 2013-10-23
TR201904224T4 (tr) 2019-05-21
ZA201208579B (en) 2015-05-27
JP2013529202A (ja) 2013-07-18
NZ603560A (en) 2014-09-26

Similar Documents

Publication Publication Date Title
BR112012029067A2 (pt) grupos-alvo de receptor do complemento 2 (cr2) melhorados.
EA201201047A1 (ru) Способы и композиции, в которых применяют слитые полипептиды fgf 23
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
WO2016022994A3 (en) High affinity pd-1 agents and methods of use
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
BR112018075363A2 (pt) neurotoxinas botulínicas manipuladas
HRP20192174T1 (hr) Kombinirani farmaceutski pripravak
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112015004696A2 (pt) polipeptídeos quiméricos tendo especificidade de ligação alvejada
PE20142114A1 (es) Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
BR112022005602A2 (pt) Células efetoras de múltiplos direcionamentos e uso das mesmas
RS54340B1 (en) ACE2 POLYPEPTID
BRPI0701810A (pt) produto alimentìcio, barra alimentìcia, mistura de proteìna, e, método para fabricar uma barra alimentìcia
BR112013003361A2 (pt) anticorpo, polinucleotídeo e polipeptídeo isolado, composição, vetor, célual hospedeira, método de produção de um anticorpo, conjugado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos de tratamento, de indução e de diagnóstico de doença em um indivíduo
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
DK2167656T3 (da) Meganucleasevarianter, som spalter en DNA-målsekvens fra muse-ROSA26-locusset, og anvendelser deraf
BRPI1013877A2 (pt) Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
BR112012013868A8 (pt) composição, proteína de fusão, polinucleotídeo, vetor ou constructo de gene, célula hospedeira , composição farmacêutica, método in vitro e uso de uma composição.
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
BR112017012928A2 (pt) uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.